A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Inclusion Criteria:

• Participants diagnosed with Atopic Dermatitis (AD) as defined by the Hanifin andRajka criteria.

• Participants with AD duration of at least 3 months (participant/parent/guardian mayverbally report signs and symptoms of AD with onset at least 3 months prior).

• Participants with IGA score of 2 to 3 at the screening and baseline visits.

• Participants with %BSA (excluding scalp) of AD involvement of 3% to 20% at screeningand baseline visits.

• For children aged 6 years to < 12 years, baseline itch NRS score ≥ 4.

• Participants/guardians who agree to discontinue all agents used by the participantto treat AD from the screening visit through the final safety follow-up visit.

• Participants with at least 1 target lesion that measures at least 5 cm2 at thescreening and baseline visits. The target lesion must be representative of theparticipant's disease state but not located on the hands, feet, or genitalia.

• Willingness to avoid pregnancy or fathering a child for the duration of studyparticipation.

Exclusion Criteria:

• An unstable course of AD (spontaneously improving or rapidly deteriorating) asdetermined by the investigator over the previous 4 weeks before the baseline visit.

• Concurrent conditions and history of other diseases as follows:

1. Immunocompromised

2. Chronic or acute infection requiring treatment with systemic antibiotics,antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeksbefore the baseline visit.

3. Active acute bacterial, fungal, or viral skin infection within 1 week beforethe baseline visit.

4. Any other concomitant skin disorder, pigmentation, or extensive scarring thatin the opinion of the investigator may interfere with the evaluation of ADlesions or compromise participant safety.

5. Presence of AD lesions only on the hands or feet without prior history ofinvolvement of other classic areas of involvement such as the face or theflexural folds.

6. Other types of eczema.

7. Chronic asthma requiring more than 880 µg of inhaled budesonide or equivalenthigh dose of other inhaled corticosteroids.

• Any serious illness or medical, physical, or psychiatric condition(s) that, in theinvestigator's opinion, would interfere with full participation in the study,including administration of study drug and attending required study visits; pose asignificant risk to the participant; or interfere with interpretation of study data.

• Use of any of the following treatments within the indicated washout period beforethe baseline visit:

1. 5 half-lives or 12 weeks, whichever is longer - biologic agents (eg,dupilumab).

2. 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogues,cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive orimmunomodulating agents (eg, mycophenolate or tacrolimus).

3. 2 weeks - immunizations with activated vaccines; sedating antihistamines unlesson a long-term stable regimen (nonsedating antihistamines are permitted). Note:Live vaccines are not recommended during the VC period.

4. 1 week - use of topical treatments for AD (other than bland emollients, eg,Aveeno® creams, ointments, sprays, soap substitutes), such as corticosteroids,calcineurin inhibitors, PDE4 inhibitors, coal tar (shampoo), topicalantibiotics, or antibacterial cleansing body wash/soap. Note: Diluted sodiumhypochlorite "bleach" baths are allowed as long as they do not exceed 2 bathsper week.

• Participants who have previously received JAK inhibitors, systemic or topical. -Ultraviolet light therapy or prolonged exposure to natural or artificial sources ofUV radiation (eg, sunlight or tanning booth) within 2 weeks prior to the baselinevisit and/or intention to have such exposure during the study, which is thought bythe investigator to potentially impact the participant's AD.-

• Positive serology test results at screening for HIV antibody.

• Current treatment or treatment within 30 days or 5 half-lives (whichever is longer)before the baseline visit with another investigational medication or currentenrollment in another investigational drug protocol.

• In the opinion of the investigator, unable or unlikely to comply with theadministration schedule and study evaluations.

• Employees of the sponsor or investigator or otherwise dependents of them.